Genmab CEO: Important data on the horizon
![](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article6279491.ece/ALTERNATES/schema-16_9/JanVanDerWinkel02.jpg)
Several analysts had anticipated that Genmab and commercial partner GlaxoSmithKline (GSK) would win approval for Arzerra to treat patients with chronic lymphocytic leukemia (CLL) in combination with chemotherapy Bendamustin, but that combination will still only be available to patients off-label.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
The boss’s plan: New Genmab a force to be reckoned with
For abonnenter
Genmab CEO: Preparing the company for the future
For abonnenter